GlassScriptPhysician profile
Juan Cevallos
NPI 1881705143
$2,527.77
in general payments reported to CMS, 2019-2025
24 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $292 · 2021: $24.38 · 2022: $181 · 2023: $135 · 2024: $561 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,534 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.10 |
| Education | $193.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $827.90 | 2019-2025 | Trelegy Ellipta, Nucala |
| Jazz Pharmaceuticals INC. | $352.12 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $219.78 | 2020-2024 | Fasenra |
| Inspire Medical Systems, INC. | $193.82 | 2023-2025 | Inspire |
| Philips North America LLC | $128.68 | 2019-2025 | (Ae4) Secretion Management, Vest Therapy Und |
| Harmony Biosciences LLC | $100.09 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $83.58 | 2019-2025 | Dupixent |
| Insmed, INC. | $74.32 | 2024-2025 | Arikayce |
| United Therapeutics Corporation | $73.67 | 2024 | Orenitram, Remodulin |
| Verona Pharma, INC. | $70.68 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.19 | 2022-2024 | Ofev |
| Axsome Therapeutics, INC. | $59.56 | 2024-2025 | Sunosi |
| Amgen INC. | $34.00 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $31.06 | 2019-2021 | |
| Gilead Sciences, INC. | $30.90 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $28.13 | 2023 | |
| Merck Sharp & Dohme LLC | $26.51 | 2025 | Winrevair |
| Avadel Cns Pharmaceuticals, LLC | $25.28 | 2025 | Lumryz |
| Inogen, INC. | $24.53 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Grifols USA, LLC | $22.28 | 2025 | Prolastin-C Liquid |
| Boston Scientific Corporation | $16.81 | 2024 | Varithena Administration Pack |
| Genentech USA, INC. | $13.69 | 2019 | |
| Eisai INC. | $13.15 | 2020 | |
| Mylan Specialty L.P. | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Cevallos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.